BR0009676A - Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica - Google Patents
Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêuticaInfo
- Publication number
- BR0009676A BR0009676A BR0009676-8A BR0009676A BR0009676A BR 0009676 A BR0009676 A BR 0009676A BR 0009676 A BR0009676 A BR 0009676A BR 0009676 A BR0009676 A BR 0009676A
- Authority
- BR
- Brazil
- Prior art keywords
- atovaquone
- primaquine
- combination
- proguanil
- treatment
- Prior art date
Links
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 title abstract 6
- 229960003159 atovaquone Drugs 0.000 title abstract 6
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 title abstract 5
- 229960005179 primaquine Drugs 0.000 title abstract 4
- 201000004792 malaria Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005385 proguanil Drugs 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BSJMWHQBCZFXBR-UHFFFAOYSA-N 3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone Chemical compound O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 BSJMWHQBCZFXBR-UHFFFAOYSA-N 0.000 abstract 1
- 241000223810 Plasmodium vivax Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"MéTODO PARA O TRATAMENTO E/OU PROFILAXIA DE MALáRIA, USOS DE ATOVAQUONA E DE UMA COMBINAçãO DE ATOVAQUONA, PROGUANILA E PRIMAQUINA, COMBINAçãO DE ATOVAQUONA, PROGUANILA E PRIMAQUINA, KIT, E, FORMULAçãO FARMACêUTICA". Métodos de tratamento e prevenção de infecção de malária causada por Plasmodium vivax, em que combinações de atovaquona, proguanila e primaquina são administradas a um paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12867299P | 1999-04-09 | 1999-04-09 | |
PCT/US2000/009091 WO2000061133A1 (en) | 1999-04-09 | 2000-04-05 | Combination preparation for treating malaria |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0009676A true BR0009676A (pt) | 2002-09-03 |
Family
ID=22436426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009676-8A BR0009676A (pt) | 1999-04-09 | 2000-04-05 | Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica |
Country Status (24)
Country | Link |
---|---|
US (1) | US6413993B1 (pt) |
EP (1) | EP1171108B1 (pt) |
JP (1) | JP2002541196A (pt) |
KR (1) | KR100613805B1 (pt) |
CN (1) | CN1152676C (pt) |
AT (1) | ATE241971T1 (pt) |
AU (1) | AU758167B2 (pt) |
BR (1) | BR0009676A (pt) |
CA (1) | CA2369089A1 (pt) |
CZ (1) | CZ294903B6 (pt) |
DE (1) | DE60003175T2 (pt) |
DK (1) | DK1171108T3 (pt) |
ES (1) | ES2199817T3 (pt) |
HK (1) | HK1041638A1 (pt) |
HU (1) | HUP0200842A3 (pt) |
IL (2) | IL145609A0 (pt) |
MX (1) | MXPA01010125A (pt) |
NO (1) | NO20014806L (pt) |
NZ (1) | NZ514353A (pt) |
PL (1) | PL350987A1 (pt) |
PT (1) | PT1171108E (pt) |
TR (1) | TR200102843T2 (pt) |
WO (1) | WO2000061133A1 (pt) |
ZA (1) | ZA200108254B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
US20090280069A1 (en) * | 2008-05-09 | 2009-11-12 | Tolmar, Inc. | Proguanil to treat skin/mucosal diseases |
EP2318350A4 (en) * | 2008-07-25 | 2012-11-28 | Alphapharm Pty Ltd | ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM |
EP2467358B1 (en) * | 2009-08-20 | 2014-07-23 | IPCA Laboratories Limited | Novel complex for treatment and/or prophylaxis of parasitic infections |
EP3415147A4 (en) * | 2016-02-12 | 2019-07-10 | Kao Corporation | MELANIN DEGRADATION INHIBITOR |
US20200155481A1 (en) * | 2017-05-03 | 2020-05-21 | The Johns Hopkins University | Intramuscular atovaquone for malaria prophylaxis |
CN107737108B (zh) * | 2017-12-17 | 2018-06-26 | 姚蕾 | 一种治疗心肌梗死后心室重塑的口服药物组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224739D0 (en) | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
JPH0873355A (ja) * | 1994-09-02 | 1996-03-19 | Mitsui Toatsu Chem Inc | 抗マラリア薬耐性克服剤 |
-
2000
- 2000-04-05 US US09/958,402 patent/US6413993B1/en not_active Expired - Fee Related
- 2000-04-05 HU HU0200842A patent/HUP0200842A3/hu unknown
- 2000-04-05 AT AT00921746T patent/ATE241971T1/de not_active IP Right Cessation
- 2000-04-05 DK DK00921746T patent/DK1171108T3/da active
- 2000-04-05 JP JP2000610466A patent/JP2002541196A/ja active Pending
- 2000-04-05 IL IL14560900A patent/IL145609A0/xx active IP Right Grant
- 2000-04-05 MX MXPA01010125A patent/MXPA01010125A/es active IP Right Grant
- 2000-04-05 BR BR0009676-8A patent/BR0009676A/pt not_active Application Discontinuation
- 2000-04-05 DE DE60003175T patent/DE60003175T2/de not_active Expired - Lifetime
- 2000-04-05 PL PL00350987A patent/PL350987A1/xx not_active Application Discontinuation
- 2000-04-05 CN CNB008060649A patent/CN1152676C/zh not_active Expired - Fee Related
- 2000-04-05 TR TR2001/02843T patent/TR200102843T2/xx unknown
- 2000-04-05 AU AU42022/00A patent/AU758167B2/en not_active Ceased
- 2000-04-05 CA CA002369089A patent/CA2369089A1/en not_active Abandoned
- 2000-04-05 PT PT00921746T patent/PT1171108E/pt unknown
- 2000-04-05 NZ NZ514353A patent/NZ514353A/en not_active IP Right Cessation
- 2000-04-05 EP EP00921746A patent/EP1171108B1/en not_active Expired - Lifetime
- 2000-04-05 CZ CZ20013646A patent/CZ294903B6/cs not_active IP Right Cessation
- 2000-04-05 KR KR1020017012799A patent/KR100613805B1/ko not_active IP Right Cessation
- 2000-04-05 WO PCT/US2000/009091 patent/WO2000061133A1/en active IP Right Grant
- 2000-04-05 ES ES00921746T patent/ES2199817T3/es not_active Expired - Lifetime
-
2001
- 2001-09-24 IL IL145609A patent/IL145609A/en not_active IP Right Cessation
- 2001-10-03 NO NO20014806A patent/NO20014806L/no not_active Application Discontinuation
- 2001-10-08 ZA ZA200108254A patent/ZA200108254B/xx unknown
-
2002
- 2002-04-16 HK HK02102862A patent/HK1041638A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010108468A (ko) | 2001-12-07 |
WO2000061133A1 (en) | 2000-10-19 |
US6413993B1 (en) | 2002-07-02 |
HUP0200842A3 (en) | 2006-07-28 |
IL145609A0 (en) | 2002-06-30 |
NZ514353A (en) | 2003-10-31 |
ES2199817T3 (es) | 2004-03-01 |
NO20014806L (no) | 2001-12-05 |
CN1152676C (zh) | 2004-06-09 |
NO20014806D0 (no) | 2001-10-03 |
AU4202200A (en) | 2000-11-14 |
MXPA01010125A (es) | 2002-06-04 |
KR100613805B1 (ko) | 2006-08-18 |
EP1171108B1 (en) | 2003-06-04 |
HK1041638A1 (en) | 2002-07-19 |
IL145609A (en) | 2006-04-10 |
DK1171108T3 (da) | 2003-10-06 |
DE60003175T2 (de) | 2004-04-01 |
CZ294903B6 (cs) | 2005-04-13 |
CN1346267A (zh) | 2002-04-24 |
DE60003175D1 (de) | 2003-07-10 |
ZA200108254B (en) | 2003-03-26 |
ATE241971T1 (de) | 2003-06-15 |
PL350987A1 (en) | 2003-02-24 |
PT1171108E (pt) | 2003-10-31 |
CA2369089A1 (en) | 2000-10-19 |
EP1171108A1 (en) | 2002-01-16 |
CZ20013646A3 (cs) | 2002-06-12 |
JP2002541196A (ja) | 2002-12-03 |
TR200102843T2 (tr) | 2002-01-21 |
HUP0200842A2 (hu) | 2002-07-29 |
AU758167B2 (en) | 2003-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113710A (pt) | Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade | |
GEP20053602B (en) | Aripiprazole for Oral Administration | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
UY27186A1 (es) | Formulación farmacéutica | |
BR9917007A (pt) | Moduladores de ccr5 | |
RO116342B1 (ro) | Compoziţie farmaceutică lichidă, orală | |
BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
BR0008323A (pt) | Derivado de gabapentina para a prevenção e o tratamento de dor visceral | |
BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
BR0207760A (pt) | Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição | |
BRPI0111591B8 (pt) | composto, composição farmacêutica, e, usos de um composto | |
BR9709838A (pt) | Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase | |
AU2001247968A1 (en) | Use of asiatic acid or asiaticoside for treatment of cancer | |
PT998287E (pt) | Utilizacao de levobupivacaina | |
BR9910032A (pt) | Tienopirimidinas | |
BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
BR0009676A (pt) | Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica | |
BR9814945A (pt) | Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit | |
BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
BR9810616A (pt) | Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer | |
MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
DE50113974D1 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
BR0208504A (pt) | Composição farmacêutica estável de pravastatina | |
AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |